Allogene Therapeutics annual operating cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Allogene Therapeutics Operating Cash Flow Growth & History (ALLO)
Allogene Therapeutics's operating cash flow was −$149.2M for fiscal 2025.
View full Allogene Therapeutics company overviewAllogene Therapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$149.2M | $51.1M | — |
| 2024 | 2024-12-31 | −$200.3M | $37.4M | — |
| 2023 | 2023-12-31 | −$237.7M | −$17.2M | — |
| 2022 | 2022-12-31 | −$220.5M | −$35.7M | — |
| 2021 | 2021-12-31 | −$184.8M | −$69.7M | — |
| 2020 | 2020-12-31 | −$115.1M | $22.3M | — |
| 2019 | 2019-12-31 | −$137.3M | −$92.7M | — |
| 2018 | 2018-12-31 | −$44.7M | — | — |
Allogene Therapeutics quarterly operating cash flow
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$32.0M | $7.0M | — |
| Q1 2026 | 2026-03-31 | −$12.9M | $40.0M | — |
| Q4 2025 | 2025-12-31 | −$27.6M | $9.1M | — |
| Q3 2025 | 2025-09-30 | −$29.7M | $14.4M | — |
| Q2 2025 | 2025-06-30 | −$39.0M | $24.6M | — |
| Q1 2025 | 2025-03-31 | −$52.9M | $3.0M | — |
| Q4 2024 | 2024-12-31 | −$36.7M | $17.0M | — |
| Q3 2024 | 2024-09-30 | −$44.1M | $11.4M | — |
| Q2 2024 | 2024-06-30 | −$63.6M | −$1.7M | — |
| Q1 2024 | 2024-03-31 | −$55.9M | $10.7M | — |
| Q4 2023 | 2023-12-31 | −$53.7M | $8.4M | — |
| Q3 2023 | 2023-09-30 | −$55.5M | −$7.9M | — |
| Q2 2023 | 2023-06-30 | −$61.9M | −$19.3M | — |
| Q1 2023 | 2023-03-31 | −$66.6M | $1.6M | — |
| Q4 2022 | 2022-12-31 | −$62.1M | −$16.7M | — |
| Q3 2022 | 2022-09-30 | −$47.7M | $1.2M | — |
| Q2 2022 | 2022-06-30 | −$42.5M | −$1.4M | — |
| Q1 2022 | 2022-03-31 | −$68.2M | −$18.9M | — |
| Q4 2021 | 2021-12-31 | −$45.4M | −$35.5M | — |
| Q3 2021 | 2021-09-30 | −$48.9M | −$11.3M | — |
| Q2 2021 | 2021-06-30 | −$41.2M | −$14.4M | — |
| Q1 2021 | 2021-03-31 | −$49.3M | −$8.5M | — |
| Q4 2020 | 2020-12-31 | −$10.0M | $40.3M | — |
| Q3 2020 | 2020-09-30 | −$37.6M | −$5.7M | — |
| Q2 2020 | 2020-06-30 | −$26.7M | −$1.8M | — |
| Q1 2020 | 2020-03-31 | −$40.8M | −$10.6M | — |
| Q4 2019 | 2019-12-31 | −$50.3M | −$28.8M | — |
| Q3 2019 | 2019-09-30 | −$31.9M | −$14.8M | — |
| Q2 2019 | 2019-06-30 | −$24.9M | −$18.8M | — |
| Q1 2019 | 2019-03-31 | −$30.3M | −$30.3M | — |
| Q4 2018 | 2018-12-31 | −$21.5M | — | — |
| Q3 2018 | 2018-09-30 | −$17.1M | — | — |
| Q2 2018 | 2018-06-30 | −$6.0M | — | — |
| Q1 2018 | 2018-03-31 | $5,000 | — | — |
Allogene Therapeutics operating cash flow trends
Over the last five fiscal years, Allogene Therapeutics's operating cash flow decreased from −$115.1M to −$149.2M, a change of −$34.2M. The latest reported quarter, Q2 2026, shows −$32.0M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Allogene Therapeutics source filings ↗